Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 3/20 | 0.77 |
| ▸ | CA2 | P00918 | 3/20 | 0.77 |
| ▸ | RELA | Q04206 | 1/20 | 0.72 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.71 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.70 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.69 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2448676 | 1.00 | KRAS (1.00) | KRASALDH1A1SMN1; SMN2ATML3MBTL1 | |
| SCHEMBL15155080 | 0.89 | ABCG2 (0.86) | KRASALDH1A1SMN1; SMN2ATML3MBTL1 | |
| SCHEMBL15155082 | 0.89 | ABCG2 (0.86) | KRASALDH1A1SMN1; SMN2ATML3MBTL1 | |
| SCHEMBL13018517 | 0.87 | KRAS (1.00) | KRASALDH1A1SMN1; SMN2ATML3MBTL1 | |
| SCHEMBL615818 | 0.87 | KRAS (1.00) | KRASALDH1A1SMN1; SMN2ATML3MBTL1 | |
| SCHEMBL5653173 | 0.87 | KRAS (0.79) | KRASALDH1A1SMN1; SMN2ATML3MBTL1 | |
| SCHEMBL19183065 | 0.87 | CA1 (1.00) | KRASALDH1A1SMN1; SMN2ATML3MBTL1 | |
| SCHEMBL13018515 | 0.87 | CA1 (1.00) | KRASALDH1A1SMN1; SMN2ATML3MBTL1 | |
| SCHEMBL5653179 | 0.87 | KRAS (0.79) | KRASALDH1A1SMN1; SMN2ATML3MBTL1 | |
| SCHEMBL3733260 | 0.86 | ABCG2 (0.86) | KRASALDH1A1SMN1; SMN2ATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041408-A1 | SMALL MOLECULE IMMUNOPOTENTIATOR CONJUGATES OF NFKB ACTIVATORS AS ADJUVANTS WITH ENHANCED EFFICACY AND REDUCED TOXICITY | THE UNIVERSITY OF CHICAGO | 2025-02-06 | — | — | US | disclosed |
| US-20220387561-A1 | TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO | COSTA RICAN SOCIAL SECURITY FUND / CAJA COSTARRICENSE DE SEGURO SOCIAL CCSS (CR) | 2022-12-08 | — | — | US | disclosed |
| US-20220008519-A1 | TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO | Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) (CR) | 2022-01-13 | — | — | US | disclosed |
| WO-2022008971-A2 | TREATMENT OF SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS INFECTION WITH KLOTHO | Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) (CR) | 2022-01-13 | — | — | WO | disclosed |
| US-20210346495-A1 | METHODS AND COMPOSITIONS COMPRISING AN NFKB INHIBITOR AND AN ADJUVANT | THE UNIVERSITY OF CHICAGO (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210093612-A1 | SYSTEMS AND METHODS TO TREAT PAIN LOCALLY | WARSAW ORTHOPEDIC INC (US) | 2021-04-01 | — | — | US | disclosed |
| EP-2827890-B1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | UNIV QUEENSLAND (AU) | 2019-08-28 | — | — | EP | disclosed |
| EP-2077821-B1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES | UNIV QUEENSLAND (AU) | 2019-08-14 | — | — | EP | disclosed |
| US-20190125826-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES ASSOCIATED WITH DESMOGLEIN-1 DEFICIENCY | INSERM INSTITUT NAT DE LA SANTE ET DE LA MEDICALE (FR) | 2019-05-02 | — | — | US | disclosed |
| US-20190083464-A1 | SYSTEMS AND METHODS TO TREAT PAIN LOCALLY | WARSAW ORTHOPEDIC, INC. | 2019-03-21 | — | — | US | disclosed |
| EP-2363122-A1 | Clonidine to treat pain locally | Medtronic, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| US-20100159015-A1 | Systems and Methods to Treat Pain Locally | WARSAW ORTHOPEDIC, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| EP-2043625-A1 | NFKAPPAB INHIBITORS TO TREAT PAIN LOCALLY | Medtronic, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008014066-A1 | NFKAPPAB INHIBITORS TO TREAT PAIN LOCALLY | MEDTRONIC, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| EP-1720552-A2 | METHODS FOR TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES | Arizona Board of Regents, acting for and on behalf of Arizona State University (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20060253100-A1 | Systems and Methods to Treat Pain Locally | MEDTRONIC, INC. (US) | 2006-11-09 | — | — | US | disclosed |
| US-20060024691-A1 | Novel pathways in the etiology of cancer | BUCK INSTITUTE FOR AGE RESEARCH | 2006-02-02 | — | — | US | disclosed |
| US-20050271661-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED (US) | 2005-12-08 | — | — | US | disclosed |
| US-20050261246-A1 | Methods for treating inflammatory and autoimmune diseases | THE ARIZONA BOARD OF REGENTS | 2005-11-24 | — | — | US | disclosed |
| WO-2005089736-A2 | METHODS FOR TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES | THE ARIZONA BOARD OF REGENTS, ON BEHALF OF, ARIZONA STATE UNIVERSITY (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346495-A1 | METHODS AND COMPOSITIONS COMPRISING AN NFKB INHIBITOR AND AN ADJUVANT | NFKBIA, IKBKG, NFKB2 | KRAS 2175/4885ALDH1A1 4681/4885SMN1; SMN2 3605/4885 |
| US-20250041408-A1 | SMALL MOLECULE IMMUNOPOTENTIATOR CONJUGATES OF NFKB ACTIVATORS AS ADJUVANTS WITH ENHANCED EFFICACY AND REDUCED TOXICITY | NFKBIA, NFRKB, NFKB2 | KRAS 971/4885ALDH1A1 4393/4885SMN1; SMN2 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.